Emergent BioSolutions (EBS) Other Non-Current Liabilities: 2010-2025
Historic Other Non-Current Liabilities for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to $42.6 million.
- Emergent BioSolutions' Other Non-Current Liabilities rose 18.99% to $42.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.6 million, marking a year-over-year increase of 18.99%. This contributed to the annual value of $39.1 million for FY2024, which is 35.29% up from last year.
- According to the latest figures from Q3 2025, Emergent BioSolutions' Other Non-Current Liabilities is $42.6 million, which was up 7.85% from $39.5 million recorded in Q2 2025.
- Emergent BioSolutions' Other Non-Current Liabilities' 5-year high stood at $69.5 million during Q4 2021, with a 5-year trough of $23.4 million in Q2 2023.
- Moreover, its 3-year median value for Other Non-Current Liabilities was $31.3 million (2023), whereas its average is $32.2 million.
- Per our database at Business Quant, Emergent BioSolutions' Other Non-Current Liabilities slumped by 60.00% in 2023 and then skyrocketed by 53.70% in 2025.
- Over the past 5 years, Emergent BioSolutions' Other Non-Current Liabilities (Quarterly) stood at $69.5 million in 2021, then tumbled by 40.29% to $41.5 million in 2022, then slumped by 30.36% to $28.9 million in 2023, then surged by 35.29% to $39.1 million in 2024, then rose by 18.99% to $42.6 million in 2025.
- Its Other Non-Current Liabilities stands at $42.6 million for Q3 2025, versus $39.5 million for Q2 2025 and $35.4 million for Q1 2025.